NSE: BIOCON · 7 October 2026
- Biocon Limited shares dropped 2.47% during the trading session, settling at ₹360.0 after opening at ₹367.7.
- Biocon announced that it has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill-finish unit for Semglee (insulin glargine) at its Malaysian insulin manufacturing facility. This follows an earlier regulatory approval secured from the European Medicines Agency in July for the same fill-finish line. The MHRA clearance strengthens the company's manufacturing and commercial compliance footprint for regulated markets.
- Trading volume was 1.39 times the 20-day average daily volume.
Why is Biocon Limited. share price falling on 7 October 2026?
Biocon Limited shares dropped 2.47% during the trading session, settling at ₹360.0 after opening at ₹367.7.
The broader market and sector benchmarks also reflected negative sentiment, with the Nifty falling 0.76% and the Nifty Pharma sector index declining 0.43%. Biocon's downward move outpaced the sectoral weakness, extending a softer near-term trend that includes a 5-day return of -2.78% and a 20-day return of -8.86%.
While the company recently received regulatory approvals and announced partnerships—such as the MHRA approval for its insulin fill-finish unit in Malaysia on September 25, 2026, and a 10-year Pertuzumab supply contract in Brazil on September 8, 2026—these developments serve as broader operational context rather than direct catalysts for today's price adjustment.
43.94 lakh shares traded by 7 October 2026 · 03:10 PM IST. This compares with a 20-day average daily volume of 31.50 lakh shares (1.39 times). The five-day average daily volume was 22.29 lakh shares. Separately, the NSE report for 6 October 2026 showed 35.22 lakh shares delivered, representing 75.78% of that day’s traded volume. The same report recorded 33,437 trades.
The stock declined alongside a weak broader market and pharmaceutical sector, extending its recent 20-day pullback. Elevated volume participation suggests continued selling pressure or portfolio rebalancing rather than a single same-day negative catalyst.
Latest Company Developments
Biocon announced that it has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill-finish unit for Semglee (insulin glargine) at its Malaysian insulin manufacturing facility. This follows an earlier regulatory approval secured from the European Medicines Agency in July for the same fill-finish line. The MHRA clearance strengthens the company's manufacturing and commercial compliance footprint for regulated markets.
Regulatory approvals for key manufacturing facilities enhance supply reliability and expand commercial reach in regulated international markets.
Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorization for its Pertuzumab biosimilar, branded as Pebrilzo. The product is indicated for the treatment of HER2-positive breast cancer across various disease stages. This milestone marks the first monoclonal antibody biosimilar to receive a positive CHMP opinion under the EMA's new tailored clinical development approach.
A positive CHMP recommendation is a vital step toward securing final European Commission marketing authorization and expanding the company's oncology portfolio in Europe.
Biocon signed a partnership agreement with Bahiafarma and Bionovis under Brazil's Productive Development Partnership (PDP) program, securing a 100% allocation for a 10-year supply contract for Pertuzumab. The consortium will gain exclusive access to Brazil's public healthcare market, which accounts for roughly 70% of the country's demand for the therapy. Biocon will receive milestone payments and revenue shares over the 10-year term, with phased local manufacturing planned for the medium to long term.
This long-term public sector contract secures predictable revenue streams and reinforces Biocon's market presence in Latin America's key healthcare ecosystem.
a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 15.47% on 30 June 2026. This compares with 15.49% on 29 June 2026, a change of -0.02 percentage points.
The filing reported 39 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and revenue realization timelines for the 10-year Pertuzumab supply contract in Brazil
- Final European Commission marketing authorization decision for the Pebrilzo Pertuzumab biosimilar
- Commercial uptake and supply scaling following the MHRA approval for the Malaysia insulin fill-finish unit
- Volume trends and cash delivery participation relative to the 20-day average volume
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
Biocon announced that it has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill-finish unit for Semglee (insulin glargine) at its Malaysian insulin manufacturing facility. This follows an earlier regulatory approval secured from the European Medicines Agency in July for the same fill-finish line. The MHRA clearance strengthens the company's manufacturing and commercial compliance footprint for regulated markets.
How strong was Biocon Limited.’s trading volume?
43.94 lakh shares traded, 1.39 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:10 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.